NCT06223906

Brief Summary

Valvular Heart Disease, impacting 2.5% of the population, is predominantly observed in the elderly and is on the rise. The primary conditions within this category are Aortic Stenosis and Mitral Regurgitation. These conditions are linked to considerable morbidity and mortality, presenting a formidable challenge in optimizing treatment strategies. Pathophysiology of Valvular Heart Disease remains poorly known. The aim of the present study is to identify biomarkers involved in this disease using multi-omics approaches

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200,000

participants targeted

Target at P75+ for all trials

Timeline
44mo left

Started Jan 2016

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress74%
Jan 2016Jan 2030

Study Start

First participant enrolled

January 1, 2016

Completed
8 years until next milestone

First Submitted

Initial submission to the registry

January 16, 2024

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 25, 2024

Completed
5.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2030

Last Updated

January 26, 2024

Status Verified

January 1, 2021

Enrollment Period

14 years

First QC Date

January 16, 2024

Last Update Submit

January 24, 2024

Conditions

Cardiovascular Diseases

Outcome Measures

Primary Outcomes (1)

  • All-cause death

    whether recidivation happened,whether other related disease happened

    These data is collected during follow-up visit at 12 months after discharge

Secondary Outcomes (1)

  • HF rehospitalization

    These data is collected during follow-up visit at 12 months after discharge

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with heart valve disease accorrding to Inclusion and exclusion criteria.

You may qualify if:

  • Patients clinically diagnosed with heart valve disease in Beijing Anzhen Hospital

You may not qualify if:

  • Age \< 18 years
  • Failure to obtain medical records and ultrasound data
  • Refuse follow-up

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beijing Anzhen Hospital

Beijing, Beijing Municipality, 100029, China

RECRUITING

MeSH Terms

Conditions

Cardiovascular Diseases

Study Officials

  • Jie Du, Dr

    The Key Laboratory of Remodeling-Related Cardiovascular Disease, Ministry of Education, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart,Lung and Blood Vessel Diseases

    STUDY DIRECTOR

Central Study Contacts

Yuan Wang, Dr

CONTACT

13910161443wangyuan980510@163.com

Rui Lin, Dr

CONTACT

15724230598linrui2235@163.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 16, 2024

First Posted

January 25, 2024

Study Start

January 1, 2016

Primary Completion (Estimated)

January 1, 2030

Study Completion (Estimated)

January 1, 2030

Last Updated

January 26, 2024

Record last verified: 2021-01

Locations

CN(1)